Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. (LYRA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lyra · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lyra Therapeutics, Inc.You LYRA | $1M | N/A | — | — |
 AEON Biopharma, Inc. AEON | $9M | N/A | — | -$3.95 |
 Aptevo Therapeutics Inc. APVO | $11M | N/A | — | -$8230.43 |
 Bolt Biotherapeutics, Inc. BOLT | $9M | N/A | — | -$17.85 |
 Cardio Diagnostics Holdings, Inc. CDIO | $4M | N/A | — | -$3.71 |
 Cingulate Inc. CING | $27M | N/A | — | -$4.13 |
 Cellectar Biosciences, Inc. CLRB | $8M | N/A | — | -$8.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lyra Therapeutics, Inc. (LYRA) measures how much investors pay for each dollar of the company's trailing earnings. LYRA's current PE ratio of N/A is calculated by dividing its stock price of $0.44 by its TTM earnings per share of —.
Frequently asked questions
LYRA pe ratio · 6 questionsLYRA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.44 and TTM EPS of —. Data sourced from Financial Modeling Prep via LYRA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lyra Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09